Compare Duke Energy Corp (DUK) vs Novartis AG (NVS) Price & Performance

Duke Energy CorpTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

Duke Energy Corp vs Novartis AG — how do they compare? Duke Energy Corp trades at $122.8 (market cap $96.05B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 3.1× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.52%). Which is the better fit depends on your goals.

	DUK	NVS
Market Cap	$96.05B	$295.37B
Sector	Utilities	Health
52-Week High	$133.46	$168.62
52-Week Low	$113.99	$119.31
Enterprise Value	$188.56B	$336.69B
Dividend Yield	3.52%	3.07%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

DUK

Severe storms cut power to 160,000 Duke Energy customers in Greater Cincinnati, restoration ongoing.PRNewsWire · 11 hours agoBearish Call 811 before digging to prevent nearly 4,500 utility line damages reported in 2026 so far.PRNewsWire · 23 hours agoNeutral Duke Energy prices $1.75B equity units offering to fund debt redemption and corporate needsPRNewsWire · 1 day agoNeutral View details →

NVS

BioCryst hits profitability with strong Q2 revenue, sparking takeover interest in rare disease biotech.24/7 Wall Street · 1 day agoBullish View details →

About Duke Energy Corp

Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.